What Desogestrel Cinfa Treats: Main Uses and Benefits

The primary therapeutic use of this medicine is commonly used for providing effective, continuous contraception for women of childbearing potential. The medicine is used within the clinical domain of reproductive health for management of fertility risk, which supports patient control over reproductive planning. The main therapeutic uses include is applied in situations involving fertility risk management, providing an option for women with contraindications to estrogen, and is considered relevant during the postpartum/breastfeeding period.

---

The estrogen-free profile is relevant as an alternative for patient groups with underlying risk factors, such as those who smoke or are over 35. Furthermore, consistent use may assist with providing the beneficial effect of modulating the menstrual cycle. The progestogen-only formulation may assist with supporting patients who require a specific hormonal profile. This often contributes to patients experiencing lighter periods or, in some cases, the absence of bleeding (amenorrhea), supporting improved day-to-day comfort and stability.

---

Quick Fact: Support for Heavy Menstrual Symptoms

Official Eligibility Profile

The eligibility for Desogestrel Cinfa, a progestogen-only contraceptive, is strictly defined by regulatory documents, excluding certain populations due to health risks or lack of data.

Classification	Who Must NOT Use (Contraindicated)
Absolute Contraindications	Active venous thromboembolic disorder (VTE), such as deep vein thrombosis or pulmonary embolism.
	Severe hepatic disease if liver function values have not returned to normal.
	Known or suspected sex-steroid sensitive malignancies (e.g., certain breast cancers).
	Undiagnosed vaginal bleeding or known/suspected pregnancy.

Age-Related Eligibility:

Use is established for women of child-bearing age. However, the safety and efficacy of desogestrel in adolescents below 18 years have not yet been established in formal studies, and the product is not indicated for use in elderly women.

Other Eligibility Considerations:

• Breastfeeding: Use is not contraindicated during lactation and is often the preferred hormonal contraceptive method for breastfeeding women.
• Condition-Specific Caution: Women with uncontrolled hypertension or a history of thromboembolic disorders require special monitoring. Discontinuation may be necessary if sustained hypertension or thrombosis occurs.

Interactions with other medicines and products

This medication's effectiveness can be impacted by, and can also impact, other medicines due to the way hormonal components are processed by the body's liver enzymes, primarily Cytochrome P450 3A4 (CYP3A4).

Interacting Product Categories

• Enzyme-Inducing Medicines: Drugs that induce, or increase the activity of, liver enzymes (like CYP3A4 inducers) can increase the clearance of the hormonal component. This can lead to a significant reduction in the contraceptive effect, which may result in an unintended pregnancy. This includes certain medicines used to treat epilepsy, HIV, and certain bacterial or fungal infections. An example of a specific medicine affected by this interaction pathway is lamotrigine, whose levels may be reduced, potentially leading to a loss of seizure control.
• Enzyme-Inhibiting Medicines: Conversely, some medicines that inhibit or block the activity of CYP3A4 may increase the levels of the hormonal component in the blood, potentially raising the risk of side effects.

Important Contraindicated Combination

• Hepatitis C Virus (HCV) Regimens: This product is contraindicated (must not be used) with the combination drug regimen containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir. Co-administration with these HCV medicines can lead to a significant increase in the liver enzyme ALT, posing a risk of liver injury.

Management of Interactions

If using an enzyme-inducing medicine, a reliable non-hormonal method of contraception must be used for the entire period of co-administration and for 28 days after the enzyme-inducing medicine is stopped to ensure contraceptive protection.

The mechanism of action is primarily executed by the active metabolite, Etonogestrel, which functions as a high-affinity agonist for the Progesterone Receptor (PR). This interaction drives two distinct yet complementary physiological effects.

Central Suppression of Ovulation

This mechanism acts on the Hypothalamic-Pituitary-Ovarian (HPO) axis to suppress the normal neuroendocrine signaling sequence. By engaging the PR, the drug initiates a negative feedback loop that prevents the critical Luteinizing Hormone (LH) surge from the pituitary gland. This physiological suppression of the LH surge results in the inhibition of ovulation, which is the principal mechanism of action.

Peripheral Barrier and Tissue Modulation

In parallel with its central effect, the active metabolite exerts direct action on the cervical mucosa. This modulation rapidly changes the glandular secretions, causing the production of thick, viscous mucus that creates a physical barrier that restricts sperm movement. The drug also induces structural changes in the uterine lining (endometrium). These peripheral effects function alongside the central mechanism, providing a secondary physiological action.

Instruction Map: How to use Desogestrel Cinfa — Official Administration Guidelines

---

Administration Scope

Route of administration: The medicine is a film-coated tablet intended for oral administration and is typically swallowed whole with some liquid.

Dosing schedule: The standard regimen requires one tablet daily, which contains 75 mu g of desogestrel. This single daily dose is also considered the continuous daily dose.

Timing in relation to meals: The tablet may be taken independently of food, but consistent daily intake is required.

Preparation requirements: No preparation such as crushing, mixing, or dilution is specified.

Age-group administration rules: The standard regimen applies to adults. Use in pre-menarcheal females is not indicated.

Missed-dose rules: Contraceptive protection is reduced if the interval between two tablets exceeds 36 hours (i.e., the dose is missed by more than 12 hours past the usual time). If this occurs, the missed tablet must be taken immediately, and an additional barrier method should be used for the next seven consecutive days.

Special procedural conditions: The tablet must be taken at approximately the same time each day to maintain a consistent 24-hour interval. If vomiting or severe diarrhea occurs within 3–4 hours of intake, the event is treated as a missed dose.

---

Instruction Classifications (High-Level)

Administration method type: Oral tablet.

Frequency pattern: Daily, continuous administration (no tablet-free interval).

Use-context constraints: Taking the first tablet must start on Day 1 of the menstrual cycle, or between Day 21 and Day 28 following delivery or second-trimester abortion.

---

Resulting Procedural Structure

Official step sequence:

• Take one 75 mu g tablet orally once daily.
• Maintain the same time each day for a 24-hour interval.
• Start the next 28-tablet pack immediately after the current pack is complete (continuous use).
• Adhere to the strict 12-hour missed-dose rule, using backup contraception if the dose is taken late.

Connection to the overall use protocol: The official use protocol is defined by a continuous daily dosing pattern with no scheduled breaks, a critical administration principle for this medicine. This mandates taking the 75 mu g tablet at the same time each day to maintain constant hormonal exposure. The instructions specify precise timing and starting protocols to ensure adherence to the standardized approach.

Research Evidence / Overview of Studies for Desogestrel Cinfa

Evidence for Use in Contraception

Research has explored the outcomes related to systemic or functional imbalance in women using this progestin-only method. These studies were applied in research contexts involving fluctuating or unstable symptoms and used in observational settings evaluating daily-life functioning. Research monitored the primary outcome studied, which is pregnancy, and described the observations made in that context.

Studies reported measurements of unintended pregnancy incidence in the populations observed. This evidence contributes to understanding the patterns of use observed in trials, which monitored responses over defined time intervals. These findings help contextualize how patients reported their experience.

However, results apply only to the populations studied, and evidence quality varies across studies. Research does not determine whether an individual will respond similarly, and follow-up durations were limited in certain contexts. Research provides context but not individual predictions regarding this outcome.

Research on Bleeding Patterns and Menstrual Changes

Studies also monitored outcomes describing episodic or acute changes, which are applied in studies examining patient-reported experiences related to physical discomfort. This research describes how symptom intensity or variability was measured over time. Studies monitored how outcomes evolved in the observed populations, and research describes variations in bleeding patterns. This was observed in some studies, including reports of both amenorrhea (absence of bleeding) and irregular spotting.

Evidence in Specific Populations

Research has explored this progestin-only method in specific contexts, such as in studies conducted during the postpartum period or in research exploring short-term symptom changes in adolescents. In populations like individuals who have recently given birth, research explored how outcomes evolved in the observed populations. Findings describe patterns observed in these studies related to the reproductive health outcomes that were monitored. However, sample sizes were modest in some research, and data for certain groups remain insufficient for a full evaluation. Subgroup findings are uncertain, and there is limited information for long-term outcomes in these specific groups.

Key Studies & References

1. Public Assessment Report Scientific discussion Desogestrel Centrafarm 0,075 mg, film-coated tablets (desogestrel)

Common questions about Desogestrel Cinfa (FAQ)

---

Q: Is Desogestrel Cinfa considered a 'mini-pill'?

A: Yes. Official patient guidance indicates that the medicine is a Progestogen-Only Pill (POP), which is commonly known as the mini-pill. This classification distinguishes it from combined oral contraceptives that contain estrogen.

Q: What is the reported effectiveness rate of Desogestrel Cinfa in clinical studies?

A: Official product information reports that the pill is more than 99% effective when taken correctly. This high rate of effectiveness means that fewer than 1 in 100 users are reported to become pregnant in one year.

Q: What are the described signs of a rare or serious side effect of Desogestrel Cinfa?

A: Serious risks, as described in regulatory documents, include blood clots and liver problems. Signs of a possible blood clot can include pain in the chest, legs, or groin, trouble breathing, or a sudden, severe headache. Signs of liver problems may include yellowing of the skin or eyes (jaundice).

Q: Are there any long-term health consequences described for individuals who use Desogestrel Cinfa?

A: The medication is generally considered suitable for long-term continuous use for many women. The elevated risk of certain cancers, such as breast cancer, is reported to be small and lessens after the pill is discontinued.

Q: What general types of antibiotics might interact with Desogestrel Cinfa?

A: Regulatory information describes that the contraceptive effectiveness can be reduced by certain medicines that speed up the breakdown of the hormone in the liver. This includes some medicines used to treat epilepsy, HIV, and some bacterial infections.

Q: Are herbal remedies or supplements safe to use while taking Desogestrel Cinfa?

A: Official guidance specifically addresses the herbal supplement St. John’s Wort. Using St. John’s Wort can reduce the amount of the hormone in the body, which may increase the risk of an unintended pregnancy.

Q: Is Desogestrel Cinfa structurally similar to other progestogen-only pills?

A: Desogestrel is classified as a third-generation progestogen. This chemical classification differentiates it from older Progestogen-Only Pills (POPs) that contain hormones such as norethisterone or levonorgestrel.

Q: Why is Desogestrel Cinfa sometimes mentioned as having a lower risk of thrombosis?

A: Official patient guidance suggests that the risk of blood clots (thrombosis) may be lower compared to combined oral contraceptives. This is because Desogestrel Cinfa does not contain estrogen, which is the component associated with the higher risk of certain vascular complications.

Q: Why do official documents describe Desogestrel Cinfa as highly effective?

A: The medication is described as highly effective because its primary action is the suppression of ovulation, which is the release of an egg, in nearly all cycles. This central effect is combined with a secondary action of thickening cervical mucus to create a physical barrier.

Q: Does Desogestrel Cinfa affect cholesterol or blood sugar levels?

A: Official warnings and precautions note that the medication may cause alterations in blood sugar levels (carbohydrate metabolism). Regulatory information indicates that individuals with pre-existing conditions like diabetes require special monitoring.

Q: Are there specific dietary considerations while using Desogestrel Cinfa?

A: Official drug labeling states that consuming grapefruit or grapefruit juice may change the amount of medicine the body absorbs.

Q: Is Desogestrel Cinfa typically intended for short-term or long-term use?

A: Official patient guidance indicates that the medicine is intended for continuous long-term contraception and may be an option for use until menopause.

Q: How quickly does Desogestrel Cinfa start to provide protection?

A: According to regulatory guidance, protection starts immediately if the first pill is taken on Day 1 to Day 5 of the menstrual cycle. Regulatory guidance states that if the pill is started on a day other than Day 1 to Day 5, the contraceptive protection requires two days to be fully established.

Q: How long does it take for common side effects of Desogestrel Cinfa to subside?

A: Official patient information suggests that common side effects, such as irregular bleeding or headaches, often improve or clear up within the first two to three months of continuous use. This is when the body is adjusting to the hormonal change.

Q: Does Desogestrel Cinfa affect libido or sexual desire?

A: Changes in sexual desire (libido) are reported in the official adverse reactions. Decreased libido is classified as an uncommon side effect, while increased libido is reported as a rare side effect.

Q: Does alcohol consumption impact the effectiveness of Desogestrel Cinfa?

A: Based on official interaction databases, no clinically significant major drug interaction has been found between Desogestrel and alcohol. There is no current regulatory reporting to suggest that alcohol consumption compromises the contraceptive effectiveness of the pill.

Q: Is Desogestrel Cinfa an option for people who are smokers over a certain age?

A: Official patient guidance notes that Progestogen-Only Pills (POPs) are generally considered a suitable option for women who smoke, including those over the age of 35.

Q: How long does the progestogen remain in the body after stopping Desogestrel Cinfa?

A: Official pharmacokinetics data indicates that the active metabolite, etonogestrel, has an elimination half-life of approximately 28 hours at steady state. The half-life describes the time it takes for half of the drug to be eliminated from the body.

Q: How quickly is fertility expected to return after discontinuing Desogestrel Cinfa?

A: Studies indicate that there are no reported long-term effects on fertility after stopping the pill. Ovulation and fertility are generally observed to return within a couple of months following the discontinuation of the medication.

Q: Does the efficacy of Desogestrel Cinfa change or decrease after many years of use?

A: Regulatory efficacy data supports the pill’s reliability for continuous, long-term use. Its effectiveness is not reported to decrease with the duration of use.

Q: Is Desogestrel Cinfa a generic version of a branded pill?

A: The active ingredient, Desogestrel 75 mu g, is available in multiple forms, including both the original branded product (e.g., Cerazette) and various generic equivalents produced by different manufacturers.

Q: Is there a link between Desogestrel Cinfa and changes in eyesight or vision?

A: Official adverse reactions list changes in vision, including blurred vision, as a reported side effect. Contact lens intolerance is also listed as a rare side effect.

How to Store and Dispose of Desogestrel Cinfa

The storage and disposal of Desogestrel Cinfa must strictly adhere to the conditions documented in the official regulatory labeling.

---

Required Storage Conditions

Requirement	Official Instruction
Temperature	Does not require any special temperature storage conditions. Do not store above 30°C (for similar products).
Protection	Must be stored in the original sachet/package to ensure protection from light and moisture.
Stability	Shelf-life after the first opening of the sachet is 1 month.
Safety	Keep out of the sight and reach of children.

---

Disposal Instructions

Any unused medicine must be disposed of according to local requirements. Do not throw away Desogestrel Cinfa via wastewater or household waste, as the active metabolite poses an environmental risk to fish. Patients should consult a pharmacist for guidance on proper disposal.